CV (CapsoVision, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-21 | ELIYAHOU ET AL HARARI | 10%+ Owner | Buy | — | — |
| 2026-07-10 | ELIYAHOU ET AL HARARI | 10%+ Owner | Buy | — | — |
| 2026-07-07 | ELIYAHOU ET AL HARARI | 10%+ Owner | Buy | — | — |
| 2026-07-02 | David Stanley Shields | Director | A | — | — |
| 2026-07-01 | Joanne Carol Imperial | Director | Sell | — | — |
| 2026-07-01 | Chen Lung Tsai | Director | M | — | — |
| 2026-07-01 | Michele Harari | Director | M | — | — |
| 2026-07-01 | Hui Ying Kuo | Director | M | — | — |
| 2026-07-01 | Joanne Carol Imperial | Director | M | — | — |
| 2026-07-01 | JULIA S GOUW | Director | M | — | — |
| 2026-07-01 | Wen-Herng Henry King | Director | M | — | — |
| 2026-06-03 | David Michael Garcia | Sr. VP of Finance | A | — | — |
| 2026-06-03 | Kang-Huai Wang | See Remarks | A | — | — |
| 2026-06-03 | Douglas Patrick Atkinson | Head of Global Sales | A | — | — |
| 2026-05-06 | Douglas Patrick Atkinson | Head of Global Sales | M | — | — |
| 2026-03-23 | Chen Lung Tsai | Director | A | — | — |
| 2026-03-23 | Hui Ying Kuo | Director | A | — | — |
| 2026-03-23 | Joanne Carol Imperial | Director | A | — | — |
| 2026-03-23 | JULIA S GOUW | Director | A | — | — |
| 2026-03-23 | Wen-Herng Henry King | Director | A | — | — |
| 2026-03-23 | Michele Harari | Director | A | — | — |
| 2026-02-06 | Chen Lung Tsai | Director | Buy | — | — |
| 2025-12-31 | Chen Lung Tsai | Director | M | — | — |
| 2025-12-31 | Joanne Carol Imperial | Director | M | — | — |
| 2025-12-31 | Michele Harari | Director | M | — | — |
| 2025-12-31 | Wen-Herng Henry King | Director | M | — | — |
| 2025-12-31 | Hui Ying Kuo | Director | M | — | — |
| 2025-12-31 | JULIA S GOUW | Director | M | — | — |
| 2025-11-03 | David Michael Garcia | Sr. VP of Finance | A | — | — |
| 2025-09-17 | Michele Harari | Director | A | — | — |
| 2025-09-17 | Joanne Carol Imperial | Director | A | — | — |
| 2025-09-17 | Hui Ying Kuo | Director | A | — | — |
| 2025-09-17 | Wen-Herng Henry King | Director | A | — | — |
| 2025-09-17 | Chen Lung Tsai | Director | A | — | — |
| 2025-09-17 | JULIA S GOUW | Director | A | — | — |
| 2025-08-22 | Rebecca Ann Petersen | Director of Clinical Affairs | M | — | — |
| 2025-07-08 | ELIYAHOU ET AL HARARI | 10%+ Owner | C | — | — |
| 2025-07-08 | ELIYAHOU ET AL HARARI | 10%+ Owner | C | — | — |
| 2025-07-07 | Kang-Huai Wang | See Remarks | C | — | — |
| 2025-07-07 | Wen-Herng Henry King | Director | C | — | — |
| 2025-07-07 | Chen Lung Tsai | Director | C | — | — |
| 2025-07-07 | Hui Ying Kuo | Director | C | — | — |
| 2012-06-28 | WILLIAM J DEEHAN | — | D | — | — |
| 2012-06-28 | DALE A ROCHELEAU | — | MIXED | — | — |
| 2012-06-28 | JOSEPH M KRAUS | — | D | — | — |
| 2012-06-28 | William R Sayre | — | D | — | — |
| 2012-06-28 | ROBERT G CLARKE | — | MIXED | — | — |
| 2012-06-28 | Brian Keefe | — | MIXED | — | — |
| 2012-06-28 | ROBERT L BARNETT | — | MIXED | — | — |
| 2012-06-28 | ROBERT B JOHNSTON | — | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,343,119 | — |
| — | See Remarks | 721,732 | — |
| — | Director | 120,385 | — |
| — | Head of Global Sales | 107,357 | — |
| — | Director | 61,065 | — |
| — | Director | 25,619 | — |
| — | Director of Clinical Affairs | 24,834 | — |
| — | Director | 15,263 | — |
| — | Director | 4,909 | — |
| — | Director | 3,709 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CV quote page; the site-wide leaderboard is on the insider transactions hub.